Michael S. O'Reilly, M.D.
Department of Thoracic Radiation Oncology, Division of Radiation Oncology
About Dr. O'Reilly
Michael S. O’Reilly, MD is a Professor of Radiation Oncology at the University of Texas MD Anderson Cancer Center. He is a medical doctor who specializes in the treatment of thoracic malignancies with training in angiogenesis research, cancer biology, surgery, and radiation oncology. Dr. O’Reilly’s clinical practice is in radiation oncology as part of the Thoracic Radiation Oncology service at MD Anderson. Dr. O’Reilly also runs a research laboratory within the Department of Experimental Radiation Oncology. Dr. O’Reilly worked in the angiogenesis research laboratory of Professor Judah Folkman at Children’s Hospital Boston and Harvard Medical School and focused his research efforts upon the discovery and characterization of inhibitors of angiogenesis and tumor dormancy. He discovered multiple endogenous angiogenesis inhibitors including angiostatin, endostatin, and antiangiogenic antithrombin. Ongoing studies of the influence of tumor microenvironment upon response to angiogenesis inhibitors alone and in combination with other modalities are now underway in Dr. O’Reilly’s laboratory. Dr. O’Reilly and colleagues study the interaction of antiangiogenic agents and other targeted biologics with radiation therapy and chemotherapy in a series of projects designed to produce improved efficacy and diminished toxicity in the treatment of cancer. Dr. O’Reilly’s research work has led to multiple publications and presentations and has provided the basis for clinical trials in lung cancer patients.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Education & Training
Degree-Granting Education
| 1989 | Tufts University, Boston, MA, USA, MD, Medicine |
| 1985 | Middlebury College, Middlebury, VT, USA, BA, Biology |
Board Certifications
| 2000 | American Board of Radiation Oncology |
Experience & Service
Academic Appointments
Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2019
Institutional Committee Activities
Member, Conflict of Interest Committee, 2004 - 2010
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
- Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514. e-Pub 2022. PMID: 35051703.
- Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA, STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
- Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
- Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly MS, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
- Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol 5(4):700-704, 2020. e-Pub 2020. PMID: 32395673.
- McGinnis GJ, Ning MS, Nitsch PL, O'Reilly MS, McAleer MF, Koong AC, Chang JY. Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. J Thorac Oncol 15(6):1085-1087, 2020. e-Pub 2020. PMID: 32311499.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2019. PMID: 31778797.
- Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol 5(6):872-878, 2019. e-Pub 2019. PMID: 31021390.
- Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open 1(4):e181390, 2018. e-Pub 2018. PMID: 30646121.
- Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X,O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys 100(3):730-737, 2018. e-Pub 2017. PMID: 29248169.
- Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol:JCO2017740720. e-Pub 2018. PMID: 29293386.
- Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 123(16):3031-3039, 2017. e-Pub 2017. PMID: 28346656.
- Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(4):900-907, 2017. e-Pub 2016. PMID: 28258887.
- Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly MS, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol:e172032. e-Pub 2017. PMID: 28727865.
- Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol 12(6):983-992, 2017. e-Pub 2017. PMID: 28259750.
- Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly MS, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol 122(2):274-280, 2017. e-Pub 2017. PMID: 28139305.
- Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage 51(5):832-838, 2016. e-Pub 2016. PMID: 26891607.
- Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-384, 2014. e-Pub 2014. PMID: 25466375.
- Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy. Am J Clin Oncol 37(1):77-80, 2014. e-Pub 2012. PMID: 23111360.
- Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly MS, Gold KA, Gomez DR. Do Angiotensin-Converting Enzyme Inhibitors Reduce the Risk of Symptomatic Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer After Definitive Radiation Therapy? Analysis of a Single-Institution Database. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 24161424.
- Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly MS, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 2013. PMID: 23920393.
- Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-9, 2013. e-Pub 2012. PMID: 22950385.
- Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-9, 2013. e-Pub 2013. PMID: 23300016.
- Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. J Thorac Oncol 8(2):140-6, 2013. PMID: 23328546.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2012. PMID: 23204236.
- Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly MS, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 8(6):e67054, 2013. e-Pub 2013. PMID: 23785517.
- Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly MS, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(2):e229-35, 2012. e-Pub 2012. PMID: 22608953.
- Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the VEGF Gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-50, 2012. e-Pub 2012. PMID: 22320189.
- Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18(6):1641-54, 2012. e-Pub 2012. PMID: 22275507.
- Yin M, Liao Z, Liu Z, Wang LE, O'Reilly MS, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer 118(2):528-35, 2012. e-Pub 2011. PMID: 21717429.
- Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 1:1-7, 2011. e-Pub 2011. PMID: 22649768.
- Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5(7):940-9, 2010. PMID: 20512076.
- Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10:431, 2010. e-Pub 2010. PMID: 20712888.
- McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?. Cancer 115:3233-42, 2009. PMID: 19472405.
- Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69(5):1534-43, 2007. e-Pub 2007. PMID: 17889445.
- Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16(2):239-49, 2007. PMID: 17243944.
- Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6:2652-2663, 2007. e-Pub 2007. PMID: 17913856.
- Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483, 2007. PMID: 17308046.
- O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 69:S64-6, 2007. PMID: 17848299.
- Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67:870-8, 2007. PMID: 17293237.
- Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly MS, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145-1151, 2006. PMID: 16505434.
- Marcus K, Johnson M, Adam RM, O'Reilly MS, Donovan M, Atala A, Freeman MR, Soker S. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology 25:178-187, 2005. PMID: 16193833.
- Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly MS, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. PMID: 14734449.
- Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143, 2004. PMID: 14734462.
- Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'Reilly MS, Fidler IJ, Herbst RS. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 10:8613-8619, 2004. PMID: 15623645.
- Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 3:679-687, 2004. PMID: 15197351.
- Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990-1993, 2003. PMID: 12702593.
- Chandra A, Liu H, Tucker SL, Liao ZX, Stevens C, Chang JY, Jeter M, O'Reilly MS, Mohan R, Cox JD, Komaki R, Guerrero T. IMRT reduces lung irradiation in distal esophageal cancer 3D CRT. Int J Radiat Oncol Biol Phys 57:S384-385, 2003.
- Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 237:530-535, 2003. PMID: 12677150.
- Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9:5532-5539, 2003. PMID: 14654533.
- Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 2002. PMID: 12228200.
- Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 120:1063-1068, 2002. PMID: 12149060.
- Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 2002. PMID: 12228199.
- Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207-2211, 2001. PMID: 11280788.
- Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 61:7298-7304, 2001. PMID: 11585769.
- Lewis VO, O'Reilly MS, Gehrmann M, Llinas M, Schaller J, Weissbach L. Inhibition of tumor growth by plasminogen-related protein-B. Anticancer Res 21:2287-2291, 2001. PMID: 11724284.
- Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000. PMID: 10766175.
- O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928, 1999. PMID: 10489375.
- O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568-29571, 1999. PMID: 10506224.
- Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH. Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3:41-51, 1999. PMID: 14517443.
- Boehm T, O'Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252:190-194, 1998. PMID: 9813168.
- Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101:1055-1063, 1998. PMID: 9486976.
- Claesson-Welsh, L, Welsh, M, Ito, N, Anand-Apte, B, Soker, S, Zetter, B, O'Reilly MS, Folkman, J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independent of the integrin-binding motif RGD. Proc Natl Acad Sci, USA 95:5579-5583, 1998.
- Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997. PMID: 9389480.
- O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997. PMID: 9008168.
- Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57:1329-1334, 1997. PMID: 9102221.
- Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236:651-654, 1997. PMID: 9245707.
- Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271:29461-29467, 1996. PMID: 8910613.
- O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692, 1996. PMID: 8640562.
- Parangi, S, O'Reilly MS, Christofori, G, Holmgren, L, Grosfeld, J, Folkman, J, Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007, 1996.
- Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-53, 1995. PMID: 7585012.
- O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30:325-329; discussion 329-330, 1995. PMID: 7738759.
- Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995. PMID: 7538593.
- Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574-84, 1994. PMID: 7521577.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994. PMID: 7525077.
- O'Reilly MS, Rosenthal, R, Sage, EH, Smith, S, Holmgren, L, Moses, M, Shing, Y, Folkman, J. The suppression of tumor metastases by a primary tumor. Surgical Forum 44:474-476, 1993.
Invited Articles
- O'Reilly MS. The interaction of radiation therapy and antiangiogenic therapy. Cancer J 14(4):207-213, 2008. PMID: 18677126.
- O'Reilly MS. Antiangiogenic Antithrombin. Semin Thromb Hemost 33(7):660-666, 2007. PMID: 18000792.
- Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. ZD6474: an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-249, 2007.
- O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16(1):45-50, 2006. PMID: 16378906.
- McDonald MD, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly MS, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the Society for Biological Therapy and Vascular Biology faculty of the NCI workshop on Angiogenesis Mentoring. J Immunotherapy 27:161-175, 2004.
- O'Reilly MS. Anti-vascular endothelial growth factor therapy in colon cancer. Principles & Practice of Oncology Updates 18:1-15, 2004.
- Herbst RS, O'Reilly MS. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Semin Oncol 30(4 Suppl 9):113-123, 2003. PMID: 12908142.
- Moses MA, O'Reilly MS. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med 74:375-390, 2003. PMID: 12415709.
- O'Reilly MS. Therapeutic strategies using inhibitors of angiogenesis. Methods Mol Biol 223:599-634, 2003. PMID: 12777753.
- O'Reilly MS. The combination of antiangiogenic therapy with other modalities. Cancer J 8 Suppl 1:S89-99, 2002. PMID: 12075706.
- O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 15:5-13, 1997. PMID: 9195285.
- O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79:273-294, 1997. PMID: 9002223.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471-482, 1994. PMID: 7587101.
Editorials
- O'Reilly MS. Vessel maneuvers: vaccine targets tumor vasculature. Nat Med 8:1352-1353, 2002. PMID: 12457172.
- O'Reilly, MS. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 8:3309-3310, 2002. PMID: 12429615.
Abstracts
- Guo X, Liao ZX, Komaki R, Lin S, Allen PK, Chang JY, O’Reilly MS, Bucci K, Jeter M, Guerrero T, Welsh J, Gomez D, Ajani J, Mohan R, Cox JD. Concurrent chemotherapy and proton beam therapy for esophageal cancer. ASTRO Proceedings 2009.
Book Chapters
- Ang, KK, O'Reilly MS, Meyn, RE, Milas, L. Principles of combining radiation therapy with molecular therapeutics. In: Radiation Oncology 9th Edition. Elsevier: Philadelphia, PA, 118-140, 2010.
- O'Reilly MS, Fidler IJ. The Development of Antiangiogenic Agents for the Clinic. In: Progress in Oncology 2002. Jones and Bartlett Publishers, Inc: Sudbury, 129-157, 2003.
- O'Reilly MS. Therapeutic Strategies Using Inhibitors of Angiogenesis. In: Tumor Suppressor Genes Volume 2: Regulation, Function, and Medicinal Applications. Humana Press, Inc: Totowa, 599-633, 2003.
- O'Reilly MS. Antiangiogenesis: basic principles and preclinical models. In: Principles and Practice of the Biologic Therapy of Cancer. Lippincott Williams & Wilkins: Philadelphia, PA, 827-843, 2000.
- O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. In: Regulation of Angiogenesis. Birkhauser Verlag: Basel, 273-294, 1997.
Patient Reviews
CV information above last modified September 26, 2024